Verici Dx Plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has provided a trading update demonstrating strong momentum for the three months ended 31 March 2026 (Q1 ’26).
Further to the year-end update provided on 5 February 2026, the Company has delivered strong growth in Q1 ’26. TutiviaTM testing volumes increased quarter-on-quarter by 32% to 392 (Q4 ’25: 296), significantly ahead of management expectations. Year-on-year Q1 testing volumes were up 34% (Q1 ’26 vs Q1 ’25). The average reimbursement rate remains in line with management expectations.
Seven new transplant centres ordered tests during the first quarter of the new financial year, and a second centre now includes TutiviaTM in its clinical protocols for patients during their treatment pathway.
Relationships with key transplant centres continue to deepen and a number of onboarded centres have become repeat ordering centres. Six of the repeat ordering centres grew volumes by more than 20%, including two of the largest centres by testing volumes increasing by more than 30%. The number of centres using TutiviaTM now represent 20% of annual kidney transplants in the US (based upon UNOS.org data)
In addition to the Medicare coverage noted last year, Tutivia is now approved in an additional two State Medicaid programmes (total to date, 17 States) facilitating ease and timeliness of payment processing.
In the period, Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx, Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals. This wealth of experience will be integral in continuing the strong momentum that the Company has established in Q1, with the onboarding of multiple new centres.
Verici Dx will announce its full year results for the year ended 31 December 2025 by the end of May 2026.
Sara Barrington, Chief Executive Officer, said: “We are very pleased to see further adoption of Tutivia™ and strong testing volume acceleration in the opening quarter of the year, building on the substantial growth we saw in FY25. Together with our ongoing progress in business development, this underpins our confidence in achieving further successful commercial traction across the rest of 2026 and beyond.”
